These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 20683399

  • 1. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB.
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [Abstract] [Full Text] [Related]

  • 2. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O, Kaya B, Kara PO, Gedik GK, Celik C, Ozbek O, Serdengecti M.
    Rev Esp Med Nucl Imagen Mol; 2012 Aug; 31(1):3-8. PubMed ID: 21549452
    [Abstract] [Full Text] [Related]

  • 3. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P.
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [Abstract] [Full Text] [Related]

  • 4. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN.
    Rev Esp Med Nucl Imagen Mol; 2014 Feb; 33(1):22-7. PubMed ID: 23948509
    [Abstract] [Full Text] [Related]

  • 5. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ, Liou WS, Liu RS, Hu C, Tsay DG, Liu CB.
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with ceCT and CA-125, and prognostic value.
    García-Talavera P, Alejo E, Arias P, Verdú A, Tamayo P, Gómez-Caminero F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Apr; 40(4):207-213. PubMed ID: 34218882
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ, Kim YM, Jung PS, Lee JJ, Kim JK, Kim YT, Nam JH.
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [Abstract] [Full Text] [Related]

  • 8. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J, Cui XW, Li YS, Wang SY, Yin Q, Wang XN, Gu L.
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([18F] FDG) in the detection of recurrent ovarian cancer.
    Palomar Muñoz A, Cordero García JM, Talavera Rubio P, García Vicente AM, González García B, Bellón Guardia ME, Soriano Castrejón Á, Aranda Aguilar E.
    Med Clin (Barc); 2018 Aug 10; 151(3):97-102. PubMed ID: 29276012
    [Abstract] [Full Text] [Related]

  • 10. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L, Cimitan M, Borsatti E, Baresic T, Sorio R, Giorda G, Steffan A, Balestreri L, Tatta R, Pepe G, Rubello D, Cecchin D, Canzonieri V.
    Clin Nucl Med; 2012 Aug 10; 37(8):e184-8. PubMed ID: 22785525
    [Abstract] [Full Text] [Related]

  • 11. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
    García Velloso MJ, Boán García JF, Villar Luque LM, Aramendía Beitia JM, López García G, Richter Echeverría JA.
    Rev Esp Med Nucl; 2003 Aug 10; 22(4):217-23. PubMed ID: 12846945
    [Abstract] [Full Text] [Related]

  • 12. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM, DeLoia JA, Gallion H, Avril N.
    Gynecol Oncol; 2007 Apr 10; 105(1):17-22. PubMed ID: 17208284
    [Abstract] [Full Text] [Related]

  • 13. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, Petersen H, Larsen LB, Duvnjak S, Buskevica I, Bektas S, Søe K, Jylling AM, Ewertz M, Alavi A, Høilund-Carlsen PF.
    J Clin Oncol; 2016 Jun 01; 34(16):1889-97. PubMed ID: 27001573
    [Abstract] [Full Text] [Related]

  • 14. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
    Fularz M, Adamiak P, Czepczyński R, Jarząbek-Bielecka G, Rewers A, Kędzia W, Ruchała M.
    Nuklearmedizin; 2015 Jun 01; 54(4):158-62. PubMed ID: 26076719
    [Abstract] [Full Text] [Related]

  • 15. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2002 Jun 01; 29(6):797-803. PubMed ID: 12029554
    [Abstract] [Full Text] [Related]

  • 16. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E, Soydal C, Araz M, Kir KM, Ibis E.
    Nucl Med Commun; 2012 Apr 01; 33(4):395-402. PubMed ID: 22367859
    [Abstract] [Full Text] [Related]

  • 17. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
    Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB, Lee HP.
    Eur J Nucl Med Mol Imaging; 2007 Apr 01; 34(4):480-6. PubMed ID: 17089122
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer].
    Cuenca Cuenca JI, Borrego Dorado I, Vázquez Albertino R, Gómez Camarero P, Sanz Viedma S, Fernández López R.
    Rev Esp Med Nucl; 2008 Apr 01; 27(6):411-7. PubMed ID: 19094899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.